Skip to main navigation

Skip to content
Skip to primary sidebar
Skip to footer

240.243.1201
info@glycomimetics.com

Careers
Contact Us

Investor Relations

About Us
Patients
- Clinical Trials
- Expanded Access
Pipeline
- Programs
- Therapeutic Focus
  - Acute Myeloid Leukemia (AML)
  - Sickle Cell Disease
Technology & Publications
Collaborations
Investors

PRESS RELEASES

Investor Relations

About Us
Patients
- Clinical Trials
- Expanded Access
Pipeline
- Programs
- Therapeutic Focus
  - Acute Myeloid Leukemia (AML)
  - Sickle Cell Disease
Technology & Publications
Collaborations
Investors

PRESS RELEASES

Year

February 25, 2020

GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020

February 4, 2020

GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations

January 30, 2020

First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359

January 6, 2020

GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 14 of 14

Shareholder Tools

Print

Print
Printed Materials

Printed Materials
Email Alerts

Email Alerts
Downloads

Downloads
RSS

RSS
Search

Search

Footer

Questions?

Contact GlycoMimetics Today

Get in Touch

©2020 GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans

Site Map | Terms of Use | Privacy | Contact Us